Urogen Pharma Stock Debt To Equity
| URGN Stock | USD 12.70 0.04 0.32% |
UroGen Pharma fundamentals help investors to digest information that contributes to UroGen Pharma's financial success or failures. It also enables traders to predict the movement of UroGen Stock. The fundamental analysis module provides a way to measure UroGen Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to UroGen Pharma stock.
| Last Reported | Projected for Next Year | ||
| Debt To Equity | (1.51) | (1.59) |
UroGen | Debt To Equity |
UroGen Pharma Company Debt To Equity Analysis
UroGen Pharma's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current UroGen Pharma Debt To Equity | 0.44 % |
Most of UroGen Pharma's fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, UroGen Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
UroGen Debt To Equity Driver Correlations
Understanding the fundamental principles of building solid financial models for UroGen Pharma is extremely important. It helps to project a fair market value of UroGen Stock properly, considering its historical fundamentals such as Debt To Equity. Since UroGen Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of UroGen Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of UroGen Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
UroGen Total Stockholder Equity
Total Stockholder Equity |
|
According to the company disclosure, UroGen Pharma has a Debt To Equity of 0.443%. This is 99.17% lower than that of the Biotechnology sector and 97.71% lower than that of the Health Care industry. The debt to equity for all United States stocks is 99.09% higher than that of the company.
UroGen Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses UroGen Pharma's direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of UroGen Pharma could also be used in its relative valuation, which is a method of valuing UroGen Pharma by comparing valuation metrics of similar companies.UroGen Pharma is currently under evaluation in debt to equity category among its peers.
UroGen Pharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of UroGen Pharma from analyzing UroGen Pharma's financial statements. These drivers represent accounts that assess UroGen Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of UroGen Pharma's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 685.0M | 392.5M | 212.5M | 202.3M | 182.1M | 224.6M | |
| Enterprise Value | 638.0M | 290.1M | 168.6M | 246.0M | 221.4M | 197.9M |
UroGen Pharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, UroGen Pharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to UroGen Pharma's managers, analysts, and investors.Environmental | Governance | Social |
UroGen Fundamentals
| Return On Equity | -14.81 | ||||
| Return On Asset | -0.21 | ||||
| Profit Margin | (1.29) % | ||||
| Operating Margin | (0.70) % | ||||
| Current Valuation | 408.28 M | ||||
| Shares Outstanding | 42.2 M | ||||
| Shares Owned By Insiders | 9.17 % | ||||
| Shares Owned By Institutions | 88.78 % | ||||
| Number Of Shares Shorted | 6.44 M | ||||
| Price To Earning | 239.57 X | ||||
| Price To Book | 21.00 X | ||||
| Price To Sales | 6.00 X | ||||
| Revenue | 82.71 M | ||||
| Gross Profit | 56.7 M | ||||
| EBITDA | (63.83 M) | ||||
| Net Income | (102.24 M) | ||||
| Cash And Equivalents | 111.74 M | ||||
| Cash Per Share | 4.91 X | ||||
| Total Debt | 100.21 M | ||||
| Debt To Equity | 0.44 % | ||||
| Current Ratio | 7.74 X | ||||
| Book Value Per Share | 0.60 X | ||||
| Cash Flow From Operations | (76.38 M) | ||||
| Short Ratio | 11.73 X | ||||
| Earnings Per Share | (3.02) X | ||||
| Target Price | 39.93 | ||||
| Number Of Employees | 217 | ||||
| Beta | 1.13 | ||||
| Market Capitalization | 535.93 M | ||||
| Total Asset | 178.31 M | ||||
| Retained Earnings | (679.35 M) | ||||
| Working Capital | 137.97 M | ||||
| Net Asset | 178.31 M |
About UroGen Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze UroGen Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of UroGen Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of UroGen Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with UroGen Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if UroGen Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in UroGen Pharma will appreciate offsetting losses from the drop in the long position's value.Moving against UroGen Stock
| 0.71 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
| 0.7 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.68 | BHC | Bausch Health Companies | PairCorr |
| 0.67 | GILD | Gilead Sciences | PairCorr |
| 0.56 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
The ability to find closely correlated positions to UroGen Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace UroGen Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back UroGen Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling UroGen Pharma to buy it.
The correlation of UroGen Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as UroGen Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if UroGen Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for UroGen Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out UroGen Pharma Piotroski F Score and UroGen Pharma Altman Z Score analysis. To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of UroGen Pharma. If investors know UroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about UroGen Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.02) | Revenue Per Share 2.389 | Quarterly Revenue Growth 0.209 | Return On Assets (0.21) | Return On Equity (14.81) |
The market value of UroGen Pharma is measured differently than its book value, which is the value of UroGen that is recorded on the company's balance sheet. Investors also form their own opinion of UroGen Pharma's value that differs from its market value or its book value, called intrinsic value, which is UroGen Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because UroGen Pharma's market value can be influenced by many factors that don't directly affect UroGen Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between UroGen Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if UroGen Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, UroGen Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.